Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study

Fig. 2

Metabolic endpoints following the administration of tofacitinib in RA patients with T2D. During the 6-month follow-up, a progressive reduction of insulin resistance was observed in RA patients with T2D treated with tofacitinib together with an improvement of insulin sensitivity. A trend in glycated haemoglobin reduction was also recorded. No significant effects were retrieved on fasting plasma glucose, cholesterol, triglycerides, and body mass index. At baseline, 40 patients were evaluated, 37 after 3 months, and 32 after 6 months, respectively. A HOMA2-IR, homeostasis model assessment of insulin resistance; B HOMA2-β, homeostasis model assessment of β-cell function; C FPG, fasting plasma glucose; D HbA1c, glycated haemoglobin; E cholesterol; F triglycerides; G BMI, body mass index

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us